Caliway's CBL-514 Receives Early IND Clearance in China, Accelerating Development in the World's Fastest-Growing Body Contouring Market

Summary
China Clinical Trial Cleared Ahead of Schedule—CBL-514's China clinical study (CBL-0102) received authorization to proceed from the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) ahead of the anticipated timeline, reflecting regulatory recognition of the study…
Description from Amherst Bee.
Who is covering this
-
Caliway's CBL-514 Receives Early IND Clearance in China, Accelerating Development in the World's Fastest-Growing Body Contouring Market
China Clinical Trial Cleared Ahead of Schedule—CBL-514's China clinical study (CBL-0102) received authorization to proceed from the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) ahead of the anticipated timeline, reflecting...
Comments
Comments need JavaScript.